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Down syndrome (DS) individuals are at high risk for developing Alzheimer’s disease (AD) and consequently provide a unique
opportunity to examine the factors leading to the onset of AD. This paper focuses on the neglected vascular parallels between AD
and DS that can readily be examined in DS. Several recent AD studies provide evidence that internal jugular vein (IJV) reﬂux may
result in white matter lesions and a 30% decrease in cerebrospinal ﬂuid (CSF) clearance of amyloid-β. At the same time, studies
analyzing the synthesis of amyloid-β in DS showed greater than expected amounts of Aβ than would be predicted by the increase
in gene dosage, perhaps due to slower clearance. These studies are discussed along with the possibility that the venous and CSF
dysfunction found in AD patients may be present early in life in persons with DS, leaving them particularly vulnerable to early
onset AD. Studying IJV function in DS provides an opportunity to understand the role of vascular function in the initiation of AD.
1.Introduction
The brains of most individuals with Down syndrome (DS)
who are over 40 years old will have suﬃcient neuropathology
for a postmortem diagnosis of Alzheimer’s disease (AD) and
provideanidealpopulation toexaminenovel ideasaboutthe
causation of AD. DS is a very complex genetic disorder that
produces detrimental changes to many organ systems. The
mechanism(s) by which the extra copy of chromosome 21
or parts thereof produce these changes is largely unknown
[1]. The majority of research and therapeutic eﬀorts to date
have focused on the diagnosis and surgical correction of
major heart defects associated with DS, once a major killer of
children with the condition. With the cardiovascular defects
surgically corrected, the average lifespan of persons with DS
has increased signiﬁcantly. Consequently, the spectrum of
threats to persons with DS include childhood illnesses early
in life and the development of AD later in life.
Increasing evidence indicates that AD is a neurovascular
disease, with macrovascular events such as heart attack and
stroke causing sustained hypoxia preceding disease onset [2],
although some cases of AD lack a vascular component. DS
typically presents with many vascular defects that are rarely
seen in the general population (Table 1).
Microvascular dysfunction also appears to play a signiﬁ-
cant role in AD onset and progression [5], and the vascular
endothelium may be dysfunctional in DS. Recent studies de-
scribe severe dysfunction in the endothelial system in DS [6],
including signiﬁcantly lower levels of endothelial progenitor
cells that are necessary for vascular regrowth and repair after
injury [6]. This may result from the early occurrence of oxi-
dative stress in DS [7], which has been linked to defects in
vascular epithelium [8]. Consequently, when a patient with
DS has an accident or event involving vascular injury,
that vascular system will not repair itself as quickly or as
eﬀectively as a person without DS. Additionally, AD risk is2 Current Gerontology and Geriatrics Research
Table 1: Vascular defects in Down syndrome: birth defects and prenatal vascular ﬁndings [3, 4].
Birth defects Prenatal vascular ﬁndings
Cardiac defects (VSD and ASD)
(found in 50% of persons with DS) Reverse ﬂow in the ductus venosus (90% of all DS fetuses)
Intrahepatic venous anomalies Placental hypovascularity (100%)
Pelvic vasculature malformations Intrathoracic vascular lesions (more rare, probably leads to fetal demise)
Pulmonary vein obstruction Umbilicoportal vascular anomalies (most common fetal defect in DS)
Aortopulmonary collateral arteries
Anomalous aortic arch arteries
Aberrant right subclavian artery
(found in 20–40% of persons with DS)
Moyamoya disease
Arterial dysplasia
Thrombosis of the venous sinuses
Birth defects: anomalies found at birth or later in life. May be found due to symptoms, or may be found incidentally. Some can also be found via pre-natal
ultrasound, such as the cardiac defects, and aberrant right subclavian artery.
Prenatal vascular ﬁndings: anomalies found via pre-natal ultrasound, either in a research or clinical setting. Many of these anomalies will resolve at birth.
VSD: ventricular septal defect; ASD: atrial septal defect.
increased by head trauma or stroke [2], and normal repair
and regeneration normally decline with age.
Finally, a recent review of AD research by Humpel [9]
proposes a much larger role for the vascular system as a
whole in the development of AD and details the impact
of chronic mild cerebrovascular dysfunction on the disease.
HumpelproposesthattheonsetofADisprecededbychronic
exposure to the cardiovascular risks over many years, includ-
ing hyperhomocysteinemia, hypercholesterolemia, and type-
2 diabetes, all of which cause damage to the cerebrovascular
system. Amyloid-β (Aβ) deposition may be a secondary con-
sequence of these ongoing vascular insults. DS often presents
with these risk factors, in addition to the vascular defects
and endothelial dysfunction previously described [10–12].
Therefore, the DS population should ﬁgure prominently in
studies on the onset and progression of AD.
Most of the research on DS and AD focuses on genes
related to the production of Aβ. Genetic studies have con-
ﬁrmed that the amyloid-β protein precursor (AβPP) gene
and genes associated with Aβ production are located on
chromosome 21 [13]. Persons with AD also exhibit trisomy
21 in various cell types, such as skin ﬁbroblasts, peripheral
blood lymphocytes, and brain neurons, although the rele-
vanceofthisto diseaseonset isyetto beestablished[14].The
overexpression of Aβ from the extra copy of chromosome 21
has been posited as the primary driver of AD in DS, with
overproduction of Aβ being responsible for its deposition
in the brain. Several recent imaging studies provide insight
into the very early stages of AD and suggest that vascular
changes ﬁgure prominently in the development and possibly
initiation of AD, as in DS.
2. White MatterChanges inAlzheimer Disease
Whitematterchangeshavebeenfoundeveninthepreclinical
stages of AD. Gold and colleagues [15]a n a l y z e dw h i t e
matter changes in women at high risk for developing AD
(those with at least one APOE4 allele and a family history
of dementia) and compared them to women at low risk
(no risk factors). Women at high risk of developing AD
showed several patterns of white matter changes not present
in healthy controls, including in the direct and indirect
connections to the median temporal lobes, as measured by
diﬀusion tensor imaging [15]. Additionally, Sanz-Arigita et
al. [16] used fMRI to examine resting state brain func-
tion in persons diagnosed with mild AD as compared to
healthy controls. Here, brains of persons with mild AD
showed regional changes in function in the frontal lobes,
including increased synchronization, and the caudal areas
had decreased synchronization, which may be indirectly
linked to white matter changes. Conversely the occipital and
parietal lobes were unaﬀected. Sanz-Arigita et al. conclude
that there may be a global loss of long distance connections
between the frontal and caudal regions [16]. Interestingly,
changes in the “presymptomatic individuals” [15]i n v o l v e d
connectivity largely in the frontal tracts, while individuals
with mild AD had more global changes involving long dis-
tanceconnectivity[16].Furtherstudiesarerequiredtodeter-
mine whether these results accurately indicate the pattern
of disease progression. While the two studies used diﬀerent
patient populations and imaging techniques, both support a
model of progressive change in white matter function very
early in disease progression.
3.ImpairedClearance ofAmyloid-β
The studies described above provide imaging not previously
available and are indicative of changes in the white matter
in AD, but do not address the mechanism driving these
changes. Overproduction of Aβ is thought to be the major
source of damage to white matter in AD [2]. However, a
recent study by Mawuenyega et al. provides an alternative
possibility for the accumulation of Aβ in the brain [17].
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longitudinally measure the level of Aβ in cerebrospinal ﬂuid
(CSF), as well as the clearance and production rates of Aβ.
Importantly, it should be noted that CSF clearance is largely
through the white matter and is negligible in gray matter
[18]. Mawuenyega et al. measured clearance and production
rates for Aβ42 and Aβ40 for 36 hours in 12 patients with
late-onset AD, as compared to healthy controls. The AD
group had a 30% slower Aβ clearance rate than the controls,
although no diﬀerence in average production rates was seen
between the AD group and healthy controls [17].
CSF clearance may be an important disease marker in
AD. Ott and colleagues examined increased ventricular vol-
ume as a biomarker for impaired CSF clearance [19]. They
studied the relationship between ventricular volume and the
AD-related biomarkers Aβ,t a u ,a n dp h o s p h o r y l a t e dt a ui n
controls, individuals with mild cognitive impairment, and
individuals with AD, taking ApoE genotype into account.
Here, ventricular volume was inversely related to Aβ levels
for ApoE4 controls and to tau levels in AD patients [19],
although the mechanism underlying the ApoE4 eﬀect on
ventricular volume is unclear. Wastyn et al. described the
protective eﬀects of daily consumption of caﬀeine with
regard to AD [20],whichappearstobeduetocaﬀeine’saﬀect
on the CSF system and resulting clearance of various toxins,
including Aβ and tau [20].
Taken together, these studies indicate that the onset of
ADmaynotbeduetoanoverproductionofAβ,butratherby
impaired CSF drainage and ﬂow. Therefore, further studies
are needed to determine the mechanism governing CSF
drainage and ﬂow. CSF is produced in the choroid plexus
and is reabsorbed into the bloodstream via the arachnoid
villi and venous sinuses [21]. Changes in CSF production,
pressure,andﬂowratesareaﬀectedbyexternalforcescausing
inﬂammation or leakage, including traumatic brain injury,
infection, tumors, or lumbar punctures [21]. The result of
impaired clearance may be speciﬁc to AD, reﬂecting the
extracellular presence of Aβ in contrast to tau, alpha synu-
clein, and ubiquitin, and suggests that the role of Aβ in
disease initiation and progression results from produc-
tion/secretion of Aβ rather than release of Aβ following cell
death.
The CSF system may also be inﬂuenced by changes in
vascular ﬂow and pressure of the venous systems near the
brain. Alteration of homeostasis between the CSF and the
vascular system may play an important role in the develop-
ment of AD; dysfunction in the vascular systems involved
with CSF may decrease CSF clearance from the brain,
thereby increasing Aβ in the brain resulting in disease onset.
One such age-related change in the vascular system is jug-
ular venous reﬂux, which can lead to decreased cerebral
perfusion pressure [22]. The internal jugular vein provides
the majority of the drainage pathway for cerebral venous
drainage. Jugular venous reﬂux results from pressure beyond
the competence of the IJV valves and consequent increased
backpressure limiting cerebral perfusion pressure. Jugular
venous reﬂux is linked to a variety of other neurological dis-
orders, including transient global amnesia, transient monoc-
ular blindness, multiple sclerosis, exertional headaches, and
idiopathic intracranial hypertension [22], all of which may
be linked to increased oxidative stress.
4. InternalJugular Reﬂux Increaseswith Age
Vascular events are a prominent risk factor for the devel-
opment of AD [2]. Chung and colleagues performed color-
codedduplexsonographyontheinternaljugularveins(IJVs)
of 349 subjects ranging in age from 55.6 to 89 years old
[23]. These subjects comprised a large, healthy population,
with age being the main variable among them. Overall IJV
functionchangedwithincreasingage,althoughthisoccurred
particularly in the left IJV, including increased lumen area,
increased jugular venous reﬂux, and slower velocity. These
ﬁndings are consistent with decreased left IJV outﬂow with
aging [23].
5. White Matter Changes with Jugular Reﬂux
Changes in white matter often occur with the onset of AD
[15, 16]. In a recent MRI and ultrasound study, white matter
changes were also found to be associated with IJV reﬂux
[24]. Here, MRI and ultrasound were used to analyze the
brains and IJVs, respectively, of 97 individuals ranging in age
from 55 to 90 years old. The ultrasound results were grouped
into three categories of jugular venous reﬂux: none, mild,
and severe. Persons with severe jugular venous reﬂux had
more white matter changes than either the mild or no reﬂux
groups, particularly in caudal brain regions. Further, whole
brain white matter changes were more prominent in persons
greater than 75 years old that had severe venous reﬂux [24],
consistent with previous ﬁndings.
Taken together, these studies provide a potential mech-
anism by which IJV function aﬀects CSF ﬂow, leading to
the development of AD. Speciﬁcally, IJV function declines
with age, resulting in reﬂux, slower velocity, and decreased
venous outﬂow. This decreased ﬂow produces changes in
venous pressures, which then alters pressure in the CSF
system. The CSF system decreases outﬂow from the brain to
restore homeostatic pressure in the brain. As a consequence,
Aβ begins to accumulate within the brain instead of being
clearedviatheCSF.IncreasedAβaccumulationsleadtodam-
age to white matter, beginning with the temporal lobes and
expanding to frontal and caudal regions, perhaps ultimately
leading to clinical features associated with AD.
6.Relevance to Down Syndrome
The CSF clearance study by Mawuenyega et al. [17]p r o v i d e s
evidence that, in the general population, clearance may be
more important in the etiology of AD than is production
of Aβ. Currently, no comparable studies in a DS population
have been conducted, although several studies provide indi-
rect evidence that Aβ clearance may be a factor in DS. Gyure
and colleagues found that serum levels of Aβ are 200–300%
higher in DS individuals as compared to controls [25], pos-
sibly due to overproduction of Aβ.W o l v e t a n ga n dc o w o r k e r s
examined Aβ production in relation to the predicted eﬀectof4 Current Gerontology and Geriatrics Research
genedosageandfoundthatAβ expressionis3-4timeshigher
in DS individuals, rather than 1.5 times higher as would be
predicted due to the extra chromosome 21. Wolvetang et al.
concluded that an additional transcriptional regulator of Aβ
also located on chromosome 21 may cause overexpression
of Aβ p r o t e i ni nD S[ 26]. Finally, Choj et al. examined
levels of AβPP with increasing age in a mouse model of
DS [27] and determined that DS mice expressed the same
level of AβPP as controls at 4 months of age. However, by
10 months of age, the DS mice exhibited increased levels of
AβPP [27], although Aβ40 and Aβ42 were not increased. Choj
et al. concluded that the changes in AβPP levels are due to
“multiple mechanisms of regulation” [27]. Taken together,
overproduction alone could not fully explain increased Aβ
levels. As reviewed in Wiseman et al. [28], a number of
additional genes on chromosome 21 have been implicated in
the development of AD in DS individuals, including those
involved in tau hyperphosphorylation (e.g., DYRK1A).
7. Down Syndrome andAlzheimer Disease:
VascularRisks
Given the large number of known vascular problems present
in individuals with DS, it is possible that the vascular system
associated with CSF clearance, particularly the IJVs studied
by Chung et al. [23, 24], could be impaired in DS and that
this impairment would likely begin early in life. Chronic, yet
mild, dysfunction of the IJV beginning early in life, along
with resulting impairment in CSF clearance, would leave
persons with DS particularly vulnerable to the buildup of Aβ
in the brain, which may be exacerbated by the overproduc-
tion of AβPP due to increased gene dosage.
Together, the studies described above addressed very spe-
ciﬁc questions relating to gene expression and protein pro-
duction, but did not examine CSF clearance. Based on the
CSF clearance study, one should question whether increased
production of Aβ is the only cause of high levels of Aβ in DS.
Perhaps persons with DS have severe CSF clearance issues
along with increased production. Or could it be due to com-
plicationsfromcardiovascularproblemsseeninearlylifeand
not fully corrected by surgical treatment?
T h er o l eo fI J Vr e ﬂ u xa n dC S Fc l e a r a n c eo fA β in the
development of AD in the DS population is currently un-
known. Determining whether these two conditions occur in
the DS population would help to clarify the role of over-
production of Aβ versus the role of vascular defects and
dysfunction in the development of AD for persons with DS.
Replicating the studies described above in a DS popula-
tion would provide answers to several key questions, includ-
ing the following.
CSF Clearance of Aβ in Down Syndrome.
(i) Is the rate of Aβ production increased in DS relative
to healthy controls, to AD patients?
(ii) Do adult patients with DS and AD exhibit decreased
CSF clearance of Aβ?
(iii) Do adult patients with DS, but not AD, exhibit de-
creased CSF clearance of Aβ?
(iv) Do children with DS exhibit decreased CSF clearance
of Aβ?
IJV Function and Resulting White Matter Changes in Down
Syndrome.
(i) How do the IJVs function in adults with DS, as com-
pared to healthy controls? Compared to those with
AD?
(ii) Does IJV function deteriorate more quickly in DS
than in healthy controls and/or those with AD?
(iii) Do persons with DS present with jugular reﬂux? If so,
do they also present with changes in white matter
consistent with the patients previously studied?
(iv) Do children with DS present with IJV dysfunction.
That is, at what age does jugular reﬂux begin?
Takentogether,thestudiesoutlinedabovesuggestatemporal
sequence of events beginning with increased oxidative stress,
an early feature of AD. Chronic oxidative stress, in turn, may
lead to decreased vascular function and ultimately results
in increased Aβ deposition. The increased expression of
AβPP and Aβ appears to be a compensatory response to
stress and deposition may simply reﬂect the failure of this
responsetoalleviatechronicstressinthecontextofdecreased
clearance. Studies of the DS population will aid in clarifying
these interactions, perhaps elucidating a potential point of
intervention in the development of AD pathology in these
individuals.
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